Monoamine Transporter

FFN200 dihydrochloride is a fluorescent substrate targeting the vesicular monoamine transporter 2 (VMAT2). This compound enables the selective tracing of monoamine exocytosis in neuronal cell cultures and brain tissue, making it a valuable tool for neuropharmacological studies. With fluorescence excitation and emission maxima at 352 nm and 451 nm, respectively, FFN200 dihydrochloride is well-suited for applications requiring high sensitivity and specificity in monitoring neurotransmitter release.

(R,S,S)-Dihydrotetrabenazine is a secondary alcohol metabolite derived from Tetrabenazine, functioning primarily as a poor inhibitor of the vesicular monoamine transporter 2 (VMAT2) with a Ki value of 690 nM. This compound is utilized in neuropharmacological studies to investigate the modulation of monoamine transporters and their role in diseases such as Parkinson's and Huntington's. Its unique isomeric structure allows for in-depth research into the pharmacokinetics and pharmacodynamics of related compounds.

Dihydrotetrabenazine (DHTBZ) is a selective inhibitor of the vesicular monoamine transporter 2 (VMAT2). By decreasing the monoamine content in presynaptic neurons, it plays a crucial role in the study of movement disorders. DHTBZ is essential for investigating the mechanisms underlying neurotransmitter regulation and offers potential insights into therapeutic strategies for neurological diseases.

4-Ethyl-N,N-Dmc hydrochloride is a drug derivative acting as a non-selective substrate for monoamine transporters, which enhances the release of neurotransmitters. This compound is primarily utilized in research focused on the pharmacological effects of amphetamines and related substances. Its structural modifications offer insights into the development of novel psychoactive compounds and their interactions within the central nervous system.

(-)-Tetrabenazine is a specific inhibitor of the vesicular monoamine transporter 2 (VMAT2). This compound exhibits notable biological activity in the modulation of monoamine neurotransmitter levels, making it valuable for research in neuropharmacology and the study of movement disorders. Its role as a VMAT2 inhibitor can aid in the investigation of drug development for conditions such as Huntington's disease and other neurodegenerative disorders.

(+)-Tetrabenazine-d6 is a deuterated form of the reversible inhibitor (+)-Tetrabenazine, which targets the vesicular monoamine transporter 2 (VMAT-2). This compound is utilized in research to investigate neurochemical processes and the role of monoamines in neurological disorders. Its isotopic labeling facilitates advanced metabolic studies and pharmacokinetic evaluations in biological systems.

Tetrabenazine mesylate is a potent reversible inhibitor of the vesicular monoamine transporter VMAT2, with a Kd value of 1.34 nM. This compound is primarily used in research focused on hyperactive movement disorders, including Huntington's disease, due to its ability to modulate monoamine neurotransmitter release. Tetrabenazine mesylate serves as a valuable tool for studying the underlying mechanisms of these neurological conditions and evaluating potential therapeutic approaches.

Tetrabenazine Metabolite is a potent vesicular monoamine transporter 2 (VMAT2) inhibitor, exhibiting high affinity with a Ki of 13.4 nM. This active metabolite plays a crucial role in the modulation of monoamine neurotransmitter levels and is primarily investigated for its therapeutic potential in chorea associated with Huntington’s disease and other hyperkinetic disorders. Its mechanism of action supports ongoing research in neurological disease management and treatment strategies.

VMAT2-IN-2 tosylate is a potent inhibitor of the vesicular monoamine transporter 2 (VMAT2). This compound is essential for investigating the pathophysiology of conditions such as tardive dyskinesia, where dysregulation of neurotransmitter storage and release plays a critical role. VMAT2-IN-2 tosylate may provide valuable insights into therapeutic strategies and the development of treatment options for related neurological disorders.

Trans (2,3)-Dihydrotetrabenazine is a metabolite of Tetrabenazine that primarily targets the vesicular monoamine transporter 2 (VMAT2). It exhibits significant inhibitory activity on VMAT2, contributing to altered monoamine storage and release. This compound is valuable for research applications in neuropharmacology and the study of movement disorders, providing insights into the modulation of neurotransmitter systems.

Tetrabenazine-d7 is a deuterium-labeled derivative of Tetrabenazine, a reversible inhibitor of the vesicular monoamine transporter VMAT2, demonstrating a Kd value of 1.34 nM. This compound is essential in biochemical research focused on hyperkinetic movement disorders, including Huntington's disease. The stable isotope labeling allows for enhanced tracking and analysis in metabolic studies and pharmacokinetic evaluations.

2-(tert-Butylamino)-1-phenylpropan-1-one hydrochloride is a non-selective agonist of monoamine transporters, specifically targeting dopamine (DAT), norepinephrine (NET), and serotonin (SERT). This compound exhibits significant activity in modulating monoamine neurotransmission, making it a valuable tool for investigating the biochemistry underlying depressive disorders. It serves as a useful reagent in pharmacological studies aimed at understanding the mechanisms of mood regulation and potential therapeutic approaches.

13-Hydroxyisobakuchiol is a selective inhibitor of monoamine transporters, primarily targeting the dopamine transporter (DAT) and norepinephrine transporter (NET) with IC50 values of 0.58 μM and 0.69 μM, respectively. In contrast, it exhibits significantly lower affinity for the serotonin transporter (SERT), with an IC50 of 312.02 μM. This compound is valuable for research applications related to neurodegenerative diseases, including Parkinson's disease, and mood disorders such as depression.

Cendifensine is a monoamine transporter inhibitor that targets the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). It is known for its ability to inhibit the reuptake of these key neurotransmitters, thus enhancing their availability in the synaptic cleft. This compound is primarily utilized in research to study the mechanisms of mood disorders, depression, and other neurological conditions, making it a valuable tool for neuroscientific investigations.

(2S,3S,11bR)-Dihydrotetrabenazine is a selective inhibitor of the vesicular monoamine transporter 2 (VMAT2), exhibiting a Ki value of 593 nM. This compound disrupts the vesicular transport of monoamine neurotransmitters, including dopamine and serotonin, leading to decreased synaptic release of these neurotransmitters. (2S,3S,11bR)-Dihydrotetrabenazine is valuable for research into Huntington's chorea and other hyperkinetic disorders, providing insights into potential therapeutic strategies.

4-Methyl-α-ethyltryptamine functions primarily as a monoamine transporter modulator. This compound is known to influence the release and re-uptake of monoamines within the brain, making it potentially valuable for research into neurochemical pathways. Its structural similarities to α-Ethyltryptamine suggest its utility in studying the effects of tryptamine derivatives on neurotransmitter dynamics and behavior.

VMAT2-IN-4 is a selective inhibitor of the vesicular monoamine transporter-2 (VMAT2), demonstrating an affinity with a Ki value of 560 nM for [3H]-DTBZ binding and a more potent inhibition of [3H]-DA uptake into vesicles at a Ki of 45 nM. This compound effectively disrupts monoamine neurotransmitter packaging within vesicles, making it a valuable tool for investigating the mechanisms underlying methamphetamine addiction. VMAT2-IN-4 supports research into the modulation of dopaminergic signaling and its implications in addiction studies.

FFN511 hydrochloride is a potent fluorescent false neurotransmitter (FFN) that selectively targets the vesicular monoamine transporter 2 (VMAT2). With an IC50 of 1 µM, it effectively inhibits serotonin binding to VMAT2-containing membranes. This compound enables real-time imaging of neurotransmitter release dynamics during exocytosis and is particularly useful for labeling dopamine terminals in live cortical-striatal acute slices, making it a valuable tool for studying synaptic transmission and neuropharmacology.

GZ-11608 is a potent and selective inhibitor of the vesicular monoamine transporter-2 (VMAT2) with a high affinity (Ki = 25 nM). This compound effectively reduces methamphetamine-induced dopamine release from isolated synaptic vesicles of dopaminergic neurons. Furthermore, GZ-11608 demonstrates rapid penetration into the brain and is characterized by an absence of neurotoxicity. It is a valuable tool for studying methamphetamine use disorder in therapeutic research.

3-Bromoamphetamine hydrochloride is a para-substituted amphetamine that functions as a monoamine releasing agent, primarily targeting the monoamine transporters. This compound has been shown to facilitate the release of neurotransmitters such as serotonin, dopamine, and norepinephrine, making it valuable in studies of neuropharmacology and behavior. Its applications in research include investigations of mood disorders, stimulant effects, and the underlying mechanisms of psychoactive substances.

2-Methylethcathinone hydrochloride is an isomer of the psychoactive compound ethcathinone. It primarily functions as a stimulant, exerting its effects by interacting with monoamine transporters, leading to increased levels of neurotransmitters such as dopamine and norepinephrine. This compound is utilized in research focused on neuropharmacology and the study of designer drugs, contributing to the understanding of their mechanisms of action and potential therapeutic applications.

2-Methylethcathinone (2-MEC) is an isomer of the psychoactive substance methcathinone, primarily acting as a monoamine transporter inhibitor. This compound exhibits stimulant properties, influencing the release and reuptake of neurotransmitters such as dopamine, norepinephrine, and serotonin. 2-MEC is utilized in research exploring its pharmacological effects, potential therapeutic implications, and the underlying mechanisms of psychostimulants.

2-Bromoamphetamine hydrochloride is an isomer of 4-Bromoamphetamine, primarily targeting monoamine transporters. This compound exhibits psychoactive properties, influencing neurotransmitter systems such as serotonin and dopamine. It is utilized in scientific research to explore the mechanisms underlying mood regulation and behavioral responses.

FFN 206 dihydrochloride is a selective substrate for the Vesicular Monoamine Transporter 2 (VMAT2), exhibiting an apparent Km of 1.16 μM. This fluorescent probe enables the detection of VMAT2 activity in intact cells via fluorescence microscopy, allowing for the visualization of subcellular localization to VMAT2-expressing acidic compartments while minimizing labeling of other organelles. Its application is essential for studying monoamine transport dynamics and cellular compartmentalization in neurobiological research.

Valbenazine tosylate is a selective inhibitor of the vesicular monoamine transporter 2 (VMAT2), exhibiting a Ki value in the range of 110-190 nM. It is primarily employed in research related to neuropharmacology and the treatment of movement disorders, such as tardive dyskinesia. By inhibiting VMAT2, Valbenazine tosylate modulates neurotransmitter release, making it a valuable tool for studying dopaminergic signaling and associated pathologies.

Indatraline hydrochloride is a non-selective monoamine transporter inhibitor, primarily targeting the reuptake of dopamine, serotonin, and norepinephrine. This compound is relevant for research focused on antidepressant mechanisms. Additionally, Indatraline hydrochloride induces autophagy and inhibits cell proliferation, suggesting potential applications in the study of autophagy-related diseases, including atherosclerosis and restenosis.

Florbenazine is a diagnostic imaging agent that selectively targets the vesicular monoamine transporter 2 (VMAT2) in the central nervous system. The fluorine-18 labeled derivative is utilized in positron emission tomography (PET) scanning to assess neuromodulatory functions. Research has demonstrated a significant biodistribution profile in mice, with a high striatum-to-cerebellum ratio, supporting its application in the diagnostic investigation of neurodegenerative disorders, such as dementia with Lewy bodies and Parkinson’s disease.